Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Category Primary study
JournalEuropean Journal of Cancer
Year 2014
This article has no abstract
Epistemonikos ID: a91f3d553c3cf7900f7a3e562940e7a5cc4ec8a7
First added on: Feb 06, 2025